<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217125</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-005978-30</org_study_id>
    <nct_id>NCT01217125</nct_id>
  </id_info>
  <brief_title>Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis</brief_title>
  <official_title>CLINICAL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF RAPAMYCIN IN ANGIOMYOLIPOMAS IN PATIENTS WITH TUBEROUS SCLEROSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Puigvert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Puigvert</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rapamycin is safe and effective in the
      treatment of renal angiomyolipomas in patients with tuberousclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiomyolipoma volume</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skin lesions, AML complications,</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate skin lesions Collect event realted to AML</description>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Angiomyolipoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>plasma levels between 4 and 8</description>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of tuberousclerosis Angiomyolipoma &gt;2cm age&gt;10 years

        Exclusion Criteria:

        Creatinine &gt;4 No recent AML bleeding No hepatic abnormalities (liver tests 2fold)
        Hematocrit&lt;27% Thrombocytopenia (&lt;100.000/mm3) Leukopenia (&lt;3000/mm3) Ischemic cardiopathy
        Recent surgery (2 months prior to enrollment) Pregnancy Serum cholesterol over 7.8 mmol/l
        or hypertriglyceridemia fasten(&gt;4.6 mmol/l) non controlled with drugs malignancy in the
        previous 2 years allergy to macrolides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roser Torra, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacio Puigvert, Barcelona</affiliation>
  </overall_official>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Puigvert</investigator_affiliation>
    <investigator_full_name>Roser Torra</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>tuberousclerosis, angiomyolipoma, rapamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Angiomyolipoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

